Ollin Biosciences
Updated: June 24, 2026
CEO - Jason Ehrlich
Country: USA | Funding: $430M (+)
Founded: 2023
Website: https://ollin.bio/
Ollin develops drugs for the treatment of patients with severe vision diseases, particularly diabetic macular edema. Its lead candidate, OLN324, for wet age-related macular degeneration (WAM), has demonstrated superior results compared to leading approved drugs. Another candidate, OLN102, is a potential first-in-class drug for the treatment of thyroid eye disease. OLN102 is designed to target both the IGF-1R and the thyroid-stimulating hormone receptor (TSHR).
Founded: 2023
Website: https://ollin.bio/
Ollin develops drugs for the treatment of patients with severe vision diseases, particularly diabetic macular edema. Its lead candidate, OLN324, for wet age-related macular degeneration (WAM), has demonstrated superior results compared to leading approved drugs. Another candidate, OLN102, is a potential first-in-class drug for the treatment of thyroid eye disease. OLN102 is designed to target both the IGF-1R and the thyroid-stimulating hormone receptor (TSHR).
